Roche Bets On Early-Stage Alzheimer’s: Luca Explains | Pharmaceutics_R&D | Scoop.it
In recent months, Alzheimer’s compounds have been hot news. Pfizer and Johnson & Johnson had one that flopped. Eli Lilly released mixed study results that generated a mix of hype and hope. And Merck (back stories here, here and here). And Merck is betting on one in a test with patients suffering mild to moderate symptoms. Meanwhile, another big drugmaker, Roche, is chugging along with a few compounds of its own and hopes its focus on early-stage disease will prove correct. We spoke briefly with Luca Santarelli, the head of neuroscience at Roche, about its efforts… (...) - Pharmalot, By Ed Silverman, December 11th, 2012